Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study
- PMID: 28235967
- PMCID: PMC5337722
- DOI: 10.1136/bmjopen-2016-013278
Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study
Abstract
Objectives: To clarify the social disadvantages associated with myasthenia gravis (MG) and examine associations with its disease and treatment.
Design: Cross-sectional study.
Setting and participants: We evaluated 917 consecutive cases of established MG seen at 13 neurological centres in Japan over a short duration.
Outcome measures: All patients completed a questionnaire on social disadvantages resulting from MG and its treatment and a 15-item MG-specific quality of life scale at study entry. Clinical severity at the worst condition was graded according to the MG Foundation of America classification, and that at the current condition was determined according to the quantitative MG score and MG composite. Maximum dose and duration of dose ≥20 mg/day of oral prednisolone during the disease course were obtained from the patients' medical records. Achievement of the treatment target (minimal manifestation status with prednisolone at ≤5 mg/day) was determined at 1, 2 and 4 years after starting treatment and at study entry.
Results: We found that 27.2% of the patients had experienced unemployment, 4.1% had been unwillingly transferred and 35.9% had experienced a decrease in income, 47.1% of whom reported that the decrease was ≥50% of their previous total income. In addition, 49.0% of the patients reported feeling reduced social positivity. Factors promoting social disadvantages were severity of illness, dose and duration of prednisolone, long-term treatment, and a depressive state and change in appearance after treatment with oral steroids. Early achievement of the treatment target was a major inhibiting factor.
Conclusions: Patients with MG often experience unemployment, unwilling job transfers and a decrease in income. In addition, many patients report feeling reduced social positivity. To inhibit the social disadvantages associated with MG and its treatment, greater focus needs to be placed on helping patients with MG resume a normal lifestyle as soon as possible by achieving the treatment target.
Keywords: MENTAL HEALTH; SOCIAL MEDICINE.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Conflict of interest statement
Figures
Similar articles
-
Health-related quality-of-life and treatment targets in myasthenia gravis.Muscle Nerve. 2014 Oct;50(4):493-500. doi: 10.1002/mus.24213. Epub 2014 Aug 30. Muscle Nerve. 2014. PMID: 24536040
-
Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan.J Neurol Neurosurg Psychiatry. 2018 May;89(5):513-517. doi: 10.1136/jnnp-2017-316625. Epub 2017 Nov 24. J Neurol Neurosurg Psychiatry. 2018. PMID: 29175893 Free PMC article.
-
[Correlation between oral corticosteroid therapy and present disease status in myasthenia gravis].Rinsho Shinkeigaku. 2013;53(11):1306-8. doi: 10.5692/clinicalneurol.53.1306. Rinsho Shinkeigaku. 2013. PMID: 24291969 Japanese.
-
[Clinical factors affecting quality of life and treatment targets in patients with myasthenia gravis].Rinsho Shinkeigaku. 2013;53(11):1299-302. doi: 10.5692/clinicalneurol.53.1299. Rinsho Shinkeigaku. 2013. PMID: 24291967 Review. Japanese.
-
[Therapeutic strategies against myasthenia gravis].Nihon Rinsho. 2013 May;71(5):881-6. Nihon Rinsho. 2013. PMID: 23777099 Review. Japanese.
Cited by
-
A Review of Psychiatric Comorbidity in Myasthenia Gravis.Cureus. 2020 Jul 14;12(7):e9184. doi: 10.7759/cureus.9184. Cureus. 2020. PMID: 32802619 Free PMC article. Review.
-
The Lived Experience of Myasthenia Gravis: A Patient-Led Analysis.Neurol Ther. 2021 Dec;10(2):1103-1125. doi: 10.1007/s40120-021-00285-w. Epub 2021 Oct 23. Neurol Ther. 2021. PMID: 34687427 Free PMC article.
-
The analysis of factors affecting medication adherence in patients with myasthenia gravis: a cross-sectional study.Ther Adv Neurol Disord. 2024 Apr 22;17:17562864231206877. doi: 10.1177/17562864231206877. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 38654744 Free PMC article.
-
The Influence of Loneliness and Anxiety Levels on MG-Specific Quality of Life in Patients with Myasthenia Gravis during the COVID-19 Pandemic.Int J Behav Med. 2024 Jun;31(3):414-421. doi: 10.1007/s12529-023-10234-6. Epub 2023 Oct 18. Int J Behav Med. 2024. PMID: 37851275
-
Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis.Eur J Neurol. 2024 Jul;31(7):e16280. doi: 10.1111/ene.16280. Epub 2024 Mar 24. Eur J Neurol. 2024. PMID: 38523419 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical